Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr773 Inhibitors

Olr773 inhibitors represent a fascinating class of chemical compounds that specifically interact with the Olr773 receptor, a type of olfactory receptor protein. These inhibitors are typically small molecules designed to bind to the receptor and prevent its normal function, thereby modulating the receptor's activity in response to olfactory stimuli. The Olr773 receptor, like other olfactory receptors, is part of a large family of G protein-coupled receptors (GPCRs) that play a crucial role in the detection of odorants and the initiation of olfactory signal transduction. Inhibitors targeting Olr773 can vary widely in their chemical structure, ranging from simple organic molecules to more complex compounds with multiple functional groups that confer specificity and affinity towards the receptor.

The study of Olr773 inhibitors involves a detailed understanding of the receptor's structure, which is typically explored using techniques such as X-ray crystallography, NMR spectroscopy, and molecular modeling. These inhibitors are often designed to fit precisely into the binding pocket of the Olr773 receptor, a process that requires extensive computational docking studies and structure-activity relationship (SAR) analyses. By examining how different modifications to the inhibitor's structure affect its binding affinity and selectivity, researchers can fine-tune these compounds to achieve the desired inhibitory effect. Furthermore, the synthesis of Olr773 inhibitors involves sophisticated organic chemistry techniques, including the use of protecting groups, selective functional group transformations, and chiral resolution. The development of these inhibitors not only enhances our understanding of olfactory receptor function but also provides valuable insights into the broader field of GPCR biology and the intricate mechanisms underlying olfaction.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

A kinase inhibitor that could impact cell proliferation and angiogenesis pathways.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

An EGFR inhibitor, potentially affecting epidermal growth factor receptor signaling.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

A receptor tyrosine kinase inhibitor, could modulate cell growth and angiogenesis pathways.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

A JAK1/2 inhibitor, might influence cytokine signaling and immune response.

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
$167.00
$1353.00
(1)

A kinase inhibitor, could affect VEGFR, EGFR, and RET signaling pathways.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

Targets MET, VEGFR, and AXL, potentially affecting cell migration and angiogenesis.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

A BCL-2 inhibitor, could impact apoptosis and cell survival pathways.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

A CDK4/6 inhibitor, potentially impacting cell cycle progression and proliferation.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

A MEK inhibitor, could influence MAPK/ERK signaling pathways.

Dabrafenib

1195765-45-7sc-364477
sc-364477A
sc-364477B
sc-364477C
sc-364477D
5 mg
25 mg
50 mg
100 mg
10 g
$141.00
$260.00
$278.00
$411.00
$12485.00
6
(1)

Targets BRAF kinase, might impact cell growth and proliferation pathways.